MedTrace Logo

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

NCT04408183 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2025-07-31

Study results available
· View outcomes & findings →

Summary

This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.

Conditions

Interventions

DRUG

GLS-1200

GLS-1200 is given as a nasal spray using an atomizer

DRUG

Placebo

Placebo is given as a nasal spray using an atomizer

Sponsors & Collaborators

  • GeneOne Life Science, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-10
Primary Completion
2023-01-10
Completion
2023-01-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04408183 on ClinicalTrials.gov